Antiviral drugs

Samuel, Essie; McNaught, Krysten A.; Mulbah, Jessica L.; HajiAlilou, Hazhir; Mody, Vicky; Cates, Drew W

doi:10.1016/bs.seda.2022.09.006

Cited by 4 publications

(3 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common side effect associated with both Ganciclovir and Valganciclovir is leukopenia. Moreover, a recent systemic review of 102 studies (25 human and 77 animal) assessing the long-term effects in subjects receiving a prophylactic dose of Ganciclovir observed a correlation with spermatic toxic effects in those patients [69]. Despite the effectiveness of Ganciclovir and Valganciclovir, HCMV resistance can occur due to mutations targeted to the viral kinase or DNA polymerase genes.…”

Section: Antiviral Approach To Hcmv Infectionmentioning

confidence: 99%

Antiviral Approach to Cytomegalovirus Infection: An Overview of Conventional and Novel Strategies

Bottino,

Pastrone,

Curtoni

et al. 2023

Microorganisms

View full text Add to dashboard Cite

Human cytomegalovirus (HCMV) is a herpesvirus capable of establishing a lifelong persistence in the host through a chronic state of infection and remains an essential global concern due to its distinct life cycle, mutations, and latency. It represents a life-threatening pathogen for immunocompromised patients, such as solid organ transplanted patients, HIV-positive individuals, and hematopoietic stem cell recipients. Multiple antiviral approaches are currently available and administered in order to prevent or manage viral infections in the early stages. However, limitations due to side effects and the onset of antidrug resistance are a hurdle to their efficacy, especially for long-term therapies. Novel antiviral molecules, together with innovative approaches (e.g., genetic editing and RNA interference) are currently in study, with promising results performed in vitro and in vivo. Since HCMV is a virus able to establish latent infection, with a consequential risk of reactivation, infection management could benefit from preventive treatment for critical patients, such as immunocompromised individuals and seronegative pregnant women. This review will provide an overview of conventional antiviral clinical approaches and their mechanisms of action. Additionally, an overview of proposed and developing new molecules is provided, including nucleic-acid-based therapies and immune-mediated approaches.

show abstract

Section: Antiviral Approach To Hcmv Infectionmentioning

confidence: 99%

Antiviral Approach to Cytomegalovirus Infection: An Overview of Conventional and Novel Strategies

Bottino,

Pastrone,

Curtoni

et al. 2023

Microorganisms

View full text Add to dashboard Cite

show abstract

“…Coronavirus disease 2019 (COVID-19) also named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2); it is an infectious disease which was found in China for the first time, but a few months later World Health Organization declared it as a novel worldwide pandemic. 1 By October 2021, a total of 259 million cases of infection and 5 million deaths due to COVID-19 involvement have been confirmed globally. 2 …”

Section: Introductionmentioning

confidence: 99%

“…Remdesivir therapy has common side effects such as hypersensitivity reactions, increased liver aminotransferases, and renal laboratory data. 1 However, common use of this drug may be challenged by reporting cardiovascular complications such as bradycardia, atrial fibrillation, and prolonged QTc interval.…”

Section: Introductionmentioning

confidence: 99%

A case report of QTc prolongation: Drug induced or myocarditis in Severe Acute Respiratory Syndrome Coronavirus 2

Gholipour,

Samidoost,

Moayerifar

et al. 2024

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

Remdesivir is a nucleotide prodrug of an adenosine analog. It binds to the viral Ribonucleic Acid (RNA)-dependent RNA polymerase and inhibits viral replication by terminating RNA transcription prematurely. Remdesivir has demonstrated in vitro and in vivo activity against Severe Acute Respiratory Syndrome Coronavirus 2; it also acts in vitro neutralization activity against the Omicron variant and its subvariants. We reported a 54-years-old woman admitted with Coronavirus disease 2019. Considering to require a high fraction of inspired oxygen therapy (⩾0.6) and based on lung high resolution computed tomography, Remdesivir therapy was ordered for 5 days. She experienced palpitations and dizziness 2 days after starting Remdesivir therapy. Her QTc interval was prolonged on the electrocardiogram without any significant electrolyte abnormalities or concomitant use of medications. Although the cardiac side effects of Remdesivir therapy have been well documented, in a few cases reported the association between Remdesivir therapy and QTc interval prolongation. Since, QTc interval prolongation has the potential risk of sudden cardiac death, the clinicians should be aware of mentioned association and check electrocardiogram daily, as well as other laboratory exams.

show abstract